stephen friend inspire2live discovery network 2011-10-29
DESCRIPTION
Stephen Friend, Oct 29, 2011. Inspire2Live Discovery Network, Cambridge, UKTRANSCRIPT
![Page 1: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/1.jpg)
Actionable Cancer Network Models And Open Medical Information Systems
Stephen Friend MD PhD
Sage Bionetworks (Non-Profit Organization) Seattle/ Beijing/ Amsterdam
Discovery Networks October 29th, 2011
![Page 2: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/2.jpg)
Why not use data intensive science to build models of disease
Current Reward Structures
Organizational Structures and Tools
Pilots
Opportunities
![Page 3: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/3.jpg)
What is the problem?
We need to rebuild the drug discovery process so that we be6er understand disease biology before tes8ng proprietary compounds on sick pa8ents
![Page 4: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/4.jpg)
Personalized Medicine 101: Capturing Single bases pair mutations = ID of responders
![Page 5: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/5.jpg)
Reality: Overlapping Pathways
![Page 6: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/6.jpg)
The value of appropriate representations/ maps
![Page 7: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/7.jpg)
![Page 8: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/8.jpg)
Equipment capable of generating massive amounts of data
“Data Intensive” Science- Fourth Scientific Paradigm
Open Information System
IT Interoperability
Host evolving Models in a Compute Space- Knowledge Expert
![Page 9: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/9.jpg)
![Page 10: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/10.jpg)
WHY NOT USE “DATA INTENSIVE” SCIENCE
TO BUILD BETTER DISEASE MAPS?
![Page 11: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/11.jpg)
what will it take to understand disease?
DNA RNA PROTEIN (dark maGer)
MOVING BEYOND ALTERED COMPONENT LISTS
![Page 12: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/12.jpg)
2002 Can one build a “causal” model?
![Page 13: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/13.jpg)
db/db mouse (p~10E(-30))
AVANDIA in db/db mouse
= up regulated = down regulated
Our ability to integrate compound data into our network analyses
db/db mouse (p~10E(-20) p~10E(-100))
![Page 14: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/14.jpg)
50 network papers http://sagebase.org/research/resources.php
List of Influential Papers in Network Modeling
![Page 15: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/15.jpg)
(Eric Schadt)
![Page 16: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/16.jpg)
Equipment capable of generating massive amounts of data A-
“Data Intensive” Science- Fourth Scientific Paradigm Score Card for Medical Sciences
Open Information System D-
IT Interoperability D
Host evolving Models in a Compute Space- Knowledge Expert F
![Page 17: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/17.jpg)
.
We still consider much clinical research as if we were “hunter gathers”- not sharing
![Page 18: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/18.jpg)
TENURE FEUDAL STATES
![Page 19: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/19.jpg)
Clinical/genomic data are accessible but minimally usable
Little incentive to annotate and curate data for other scientists to use
![Page 20: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/20.jpg)
Mathematical models of disease are not built to be
reproduced or versioned by others
![Page 21: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/21.jpg)
Lack of standard forms for sharing data and lack of forms for future rights and consentss
![Page 22: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/22.jpg)
Publication Bias- Where can we find the (negative) clinical data?
![Page 23: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/23.jpg)
sharing as an adoption of common standards.. Clinical Genomics Privacy IP
![Page 24: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/24.jpg)
Sage Mission
Sage Bionetworks is a non-profit organization with a vision to create a “commons” where integrative bionetworks are evolved by
contributor scientists with a shared vision to accelerate the elimination of human disease
Sagebase.org
Data Repository
Discovery Platform
Building Disease Maps
Commons Pilots
![Page 25: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/25.jpg)
Sage Bionetworks Collaborators
Pharma Partners Merck, Pfizer, Takeda, Astra Zeneca, Amgen, Johnson &Johnson
25
Foundations Kauffman CHDI, Gates Foundation
Government NIH, LSDF
Academic Levy (Framingham) Rosengren (Lund) Krauss (CHORI)
Federation Ideker, Califarno, Butte, Schadt
![Page 26: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/26.jpg)
RULES GOVERN
PLAT
FORM
NEW
MAP
S PLATFORM
Sage Platform and Infrastructure Builders- ( Academic Biotech and Industry IT Partners...)
PILOTS= PROJECTS FOR COMMONS Data Sharing Commons Pilots-
(Federation, CCSB, Inspire2Live....)
NEW TOOLS Data Tool and Disease Map Generators- (Global coherent data sets, Cytoscape,
Clinical Trialists, Industrial Trialists, CROs…)
NEW MAPS Disease Map and Tool Users-
( Scientists, Industry, Foundations, Regulators...)
RULES AND GOVERNANCE Data Sharing Barrier Breakers-
(Patients Advocates, Governance and Policy Makers, Funders...)
![Page 27: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/27.jpg)
Developing predictive models of genotype-specific sensitivity to compound treatment
Pred
ic8ve Features
(biomarkers)
Gene8c Feature Matrix Expression, copy number, somaQc mutaQons, etc.
Sensi8ve Refractory
(e.g. EC50)
Cancer samples with varying degrees of response to therapy
27
![Page 28: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/28.jpg)
Elastic net regression 500
Features
100
Features
20
Features
1 Feature
28
![Page 29: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/29.jpg)
Bootstrapping retains robust predictive features
29
![Page 30: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/30.jpg)
Our approach identifies mutations in genes upstream of MEK as top predictors of sensitivity to MEK inhibition
#1 Mut BRAF
#3 Mut NRAS
PD-‐0325901
PD-‐0325901
#9 Mut BRAF
#312 Mut NRAS
!"#$% &"#$%
'"#(%
)*!+,-% #./0-11%2/345-674+%
30
![Page 31: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/31.jpg)
Other top predictive features include expression levels of genes regulated by MEK
PraQlas et al., (2009), PNAS
#19 ETV5 expr
#8 DUSP6 expr
#5 ETV4 expr #3 NRAS mut #2 SPRY2 expr #1 BRAF mut
PD-‐0325901
!"#$% &"#$%
'"#(%
)*!+,-% #./0-11%2/345-674+%
31
![Page 32: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/32.jpg)
Model built excluding expression data identifies BRAF, NRAS, and KRAS top predictive features for both MEK inhibitors
!"#$% &"#$%
'"#(%
)*!+,-% #./0-11%2/345-674+%
BRAF mut
NRAS mut
KRAS mut
PD-‐0325901
BRAF mut
NRAS mut
KRAS mut
AZD6244
#3 KRAS mut #2 NRAS mut #1 BRAF mut
#3 KRAS mut #2 NRAS mut #1 BRAF mut
32
![Page 33: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/33.jpg)
TP53 mut
CDKN2A copy
MDM2 expr
HGF expr
CML linage EGFR mut
EGFR mut
EGFR mut
CML lineage
ERBB2 expr
BRAF mut
BRAF mut
NRAS mut
BRAF mut
NRAS mut
KRAS mut
BRAF mut
NRAS mut
KRAS mut
#1 BRAF mut
#2 NRAS mut #1 BRAF mut
#3 KRAS mut #2 NRAS mut #1 BRAF mut
#3 KRAS mut #2 NRAS mut #1 BRAF mut
#1 EGFR mut
#1 ERBB2 expr
#1 EGFR mut
#2 CML lineage #1 EGFR mut
#1 CML lineage
#1 HGF expr
#2 TP53 mut #3 CDKN2A copy #1 MDM2 expr
How accurate would predic8ve models perform for diagnos8cs?
For 11/12 compounds, the #1 predictive feature in an unbiased analysis corresponds to the known stratifier of sensitivity
33
![Page 34: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/34.jpg)
![Page 35: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/35.jpg)
Why not share clinical /genomic data and model building in the ways currently used by the software industry (power of tracking workflows and versioning
![Page 36: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/36.jpg)
Leveraging Existing Technologies
Taverna
Addama
tranSMART
![Page 37: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/37.jpg)
INTEROPERABILITY
INTEROPERABILITY
Genome Pattern CYTOSCAPE tranSMART I2B2
SYNAPSE
![Page 38: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/38.jpg)
Watch What I Do, Not What I Say Reduce, Reuse, Recycle
Most of the People You Need to Work with Don’t Work with You
My Other Computer is Amazon
sage bionetworks synapse project
![Page 39: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/39.jpg)
CTCAP Arch2POCM The FederaQon Portable Legal Consent Sage Congress Project
Select Six Pilots at Sage Bionetworks
RULES GOVERN
PLAT
FORM
NEW
MAP
S
![Page 40: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/40.jpg)
Clinical Trial Comparator Arm Partnership “CTCAP” Strategic Opportunities For Regulatory Science
Leadership and Action
FDA September 27, 2011
CTCAP
![Page 41: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/41.jpg)
Clinical Trial Comparator Arm Partnership (CTCAP)
Description: Collate, Annotate, Curate and Host Clinical Trial Data with Genomic Information from the Comparator Arms of Industry and Foundation Sponsored Clinical Trials: Building a Site for Sharing Data and Models to evolve better Disease Maps.
Public-Private Partnership of leading pharmaceutical companies, clinical trial groups and researchers.
Neutral Conveners: Sage Bionetworks and Genetic Alliance [nonprofits].
Initiative to share existing trial data (molecular and clinical) from non-proprietary comparator and placebo arms to create powerful new tool for drug development.
Started Sept 2010
![Page 42: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/42.jpg)
Shared clinical/genomic data sharing and analysis will maximize clinical impact and enable discovery
• Graphic of curated to qced to models
![Page 43: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/43.jpg)
Arch2POCM
Restructuring the PrecompeQQve Space for Drug Discovery
How to potenQally De-‐Risk High-‐Risk TherapeuQc Areas
![Page 44: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/44.jpg)
What is the problem?
We need to rebuild the drug discovery process so that we be6er understand disease biology before tes8ng proprietary compounds on sick pa8ents
![Page 45: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/45.jpg)
Jan 09
Well. Trust (£4.1M) NCGC (20HTSs)
GSK (8FTEs)
Ontario ($5.0M)
OICR (2FTEs)
UNC (3FTEs)
April 09 June 09 June 10
Pfizer (8FTEs)
Novartis (8FTEs)
A PPP to generate novel chemical probes
Sweden ($3.0M)
15 acad. labs
….more than £30M of resource….now Lilly (8FTEs)
![Page 46: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/46.jpg)
Academic, scientific, drug discovery & economic impact
Published Dec 23 2010 - already cited 30 times
Distributed to >100 labs/companies - profile in several therapeutic areas
Pharmas - started proprietary efforts
Harvard spin off - $15 M seed funding
Opened new area: Zuber et al : BRD4/ JQ1 in acute leukaemia Nature, 2011 Aug 3 Delmore et al: BRD4/ JQ1 in multiple myeloma Cell, 2011 Volume 146, 904-917, 16 Dawson et al: BRD4/ JQ1 in MLL Nature 2011, in press.
Floyed et al: BRD4 in DNA damage response Cell, revised Filippakopoulos et al: Bromodomains structure and function Cell, revised Natoli et al: BRD4 in T-cell differentiation manuscript in preparation Bradner et al: BRDT in spermatogenesis submitted
collaborations with SGC
![Page 47: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/47.jpg)
![Page 48: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/48.jpg)
The FederaQon
![Page 49: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/49.jpg)
2008 2009 2010 2011
How can we accelerate the pace of scientific discovery?
Ways to move beyond “traditional” collaborations?
Intra-lab vs Inter-lab Communication
Colrain/ Industrial PPPs Academic Unions
![Page 50: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/50.jpg)
(Nolan and Haussler)
![Page 51: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/51.jpg)
human aging: predicting bioage using whole blood methylation
!
!
!!!
!
!!!
!!
!
!
!
!
!!
!
!
!
!
!
!
!
!
!
!
! !!
!
!
!
!
!
!!!!
!
!
!
!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!!
!
!
!
!
!
!
!
!
!
!
!
!!
!
!
!
!
!
!
!
!!
!
!!
!
!
!
!
!
!
!!
!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!!
!
!
!
!
!
!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!!
!
!
!
!
!
!!!
!
!
!
!
!
40 50 60 70 80 90 100
40
60
80
100
Training Cohort: San Diego (n=170)
Chronological Age
Bio
logic
al A
ge
RMSE=3.35
!
!!
!
!
!
!
!
!
!!
!
!!
!
!
!
!
!
!
!
!!
!
!
!
!
!
!
!
! !
!
!
!!
!
!
!
!
!
!!
!
!
!!
!
!!
!!
!
!
!
!!!
!!
!
!
!
!
!
!
!!
!!
!!
!
!!
!
!!
!
!!
!
!
!
!!!
!
!
!
! !
!
!
!!
!
!
!
!!
!
!
!!
! !
!!!
!
!
!
!!
!
!
!!
!
!
!!
40 50 60 70 80 90
40
60
80
100
Validation Cohort: Utah (n=123)
Chronological Age
Bio
logic
al A
ge
RMSE=5.44
• Independent training (n=170) and validation (n=123) Caucasian cohorts • 450k Illumina methylation array • Exom sequencing • Clinical phenotypes: Type II diabetes, BMI, gender…
![Page 52: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/52.jpg)
sage federation: model of biological age
Faster Aging
Slower Aging
Clinical Association - Gender - BMI - Disease Genotype Association Gene Pathway Expression Pr
edicted Age (liver expression)
Chronological Age (years)
Age Differential
![Page 53: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/53.jpg)
Reproducible science==shareable science
Sweave: combines programmatic analysis with narrative
Sweave.Friedrich Leisch. Sweave: Dynamic generation of statistical reports using literate data analysis. In Wolfgang Härdle and Bernd Rönz,editors, Compstat 2002 –
Proceedings in Computational Statistics,pages 575-580. Physica Verlag, Heidelberg, 2002. ISBN 3-7908-1517-9
Dynamic generation of statistical reports using literate data analysis
![Page 54: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/54.jpg)
Federated Aging Project : Combining analysis + narraQve
=Sweave Vignette Sage Lab
Califano Lab Ideker Lab
Shared Data Repository
JIRA: Source code repository & wiki
R code + narrative
PDF(plots + text + code snippets)
Data objects
HTML
Submitted Paper
![Page 55: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/55.jpg)
Portable Legal Consent
(AcQvaQng PaQents)
John Wilbanks
![Page 56: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/56.jpg)
![Page 57: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/57.jpg)
![Page 58: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/58.jpg)
![Page 59: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/59.jpg)
Sage Congress Project April 20 2012
RA Parkinson’s Asthma
(Responders CompeQQons)
![Page 60: Stephen Friend Inspire2Live Discovery Network 2011-10-29](https://reader033.vdocuments.net/reader033/viewer/2022051609/5477be61b4af9fb2738b480d/html5/thumbnails/60.jpg)
Why not use data intensive science to build models of disease
Current Reward Structures
Organizational Structures and Tools
Six Pilots
Opportunities